Dri Healthcare Trust · TSX:DHT.U

Dri Healthcare Trust — Merger or Acquisition (September 2026)

7 slides from Dri Healthcare Trust's merger presentation, Sep 21, 2026

  1. Slide 1: Acquisition of a royalty on tavapadon for the treatment of Parkinson's disease

    Acquisition of a royalty on tavapadon for the treatment of Parkinson’s disease September 21, 2026 1

  2. Slide 2: Disclaimer

    Disclaimer This presentation has been prepared by DRI Healthcare Trust (“DRI Healthcare” or “DRI”). Established as an unincorporated open-ended trust in Ontario, Canada, and publicly trading since its 2021 IPO, DRI is a global leader in providing financing to advance innovation in the life sciences

  3. Slide 3: tavapadon royalty acquisition

    tavapadon royalty acquisition1 A differentiated once-daily therapy for Parkinson’s disease, acquired on terms that accelerate DRI’s growth agenda 1 A differentiated therapy on 2 Increases deployment capacity 3 Strengthens the balance sheet highly predictable terms and Adjusted EBITDA growth and comp

  4. Slide 4: tavapadon: an oral, once-daily therapy for Parkinson's disease

    tavapadon: an oral, once-daily therapy for Parkinson’s disease tavapadon has a unique mechanism of action and a differentiated clinical profile in a large, underserved market The Market The Mechanism of Action The Data2 • Parkinson’s disease (PD) is a chronic, • tavapadon is an oral, once-daily part

  5. Slide 5: Transaction terms

    Transaction terms $316 million upfront for a well-defined set of royalty, milestone and fixed payments, capped at $437.5 million tavapadon U.S. Transaction Overview What DRI Is Acquiring Net Sales Consensus2 $ millions Consideration Fixed payments $1,200 A single upfront payment of $316 million Four

  6. Slide 6: tavapadon – strategic implications

    tavapadon – strategic implications From one high-quality asset to the next generation of royalties 01 02 03 FIT FOCUS COMPOUNDING tavapadon’s cash flow characteristics In the near-term, DRI intends to tavapadon accelerates DRI’s strategy: complement the longer-dated focus on attractive pre-approval

  7. Slide 7: Thank you

    Thank you Contact us Bill Zhang ir@drihealthcare.com 7

DRI Healthcare Trust — Merger or Acquisition (September 2026) on 6ix